

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
					First Name	Last Name
P 1	AROVA0004	1	VIR	Distribution of respiratory syncytial virus subtypes A and B among children presenting with acute respiratory tract infection to Kegalla hospital, Sri Lanka.	Maduja	Divarathna
P 2	AROVA0006	1	VIR	Prevalence of respiratory syncytial virus in acute respiratory tract infections in a selected sample of children from Sri Lanka	Maduja	Divarathna
P 33	AROVA0007	1	VTT	Evaluation of respiratory syncytial virus resistant mutants to a potent human monoclonal antibody targeting the conserved epitope on antigenic site IV of RSV F protein	Aimin	Tang
P 3	AROVA0009	1	VIR	RSV Gene Expression Patterns Depend on Strain & Gene Start (GS) Signal N-Phase	Felipe-Andres	Piedra
P 120	AROVA0010	2	EE	Risk factors associated with severe infection by Respiratory Syncytial Virus in children with Acute Bronchiolitis in Rionegro, Antioquia	Jefferson	Buendia
P 121	AROVA0011	2	EE	Burden of disease associated with respiratory syncytial virus infection in Colombia	Jefferson	Buendia
P 35	AROVA0017	1	VTT	A Novel RSV Vaccine Design against Suppression of Vaccine Enhanced Disease	Bin	Wang
P 171	AROVA0019	2	IMM	Vaccination with a single-cycle respiratory syncytial virus is immunogenic and protective in mice	Megan	Schmidt
P 90	AROVA0020	2	CS	RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling for Predictions in Pediatric Patients	Luzelena	Caro
P 172	AROVA0022	2	IMM	The role of short-chain fatty acids during Respiratory Syncytial Virus infection	Ana	Souza
P 4	AROVA0023	1	VIR	Surveillance of respiratory viruses in the outpatient setting in rural coastal Kenya: baseline epidemiological observations	Joyce	Nyiro
P 122	AROVA0024	2	EE	The health and economic burden of respiratory syncytial virus among children less than five years in New Zealand, 2012-2015	Namrata	Prasad
P 123	AROVA0025	2	EE	The health and economic burden of respiratory syncytial virus among adults aged 50 years or more in New Zealand, 2012-2015	Namrata	Prasad
P 173	AROVA0026	2	IMM	The impact of sequential overlapping infections with respiratory syncytial virus and influenza A virus on the host immune response and disease severity	Stacey	Hartwig
P 124	AROVA0027	2	EE	Respiratory syncytial virus-associated severe respiratory illness among children	Meredith	McMorrow
P 125	AROVA0028	2	EE	Community burden and household transmission of respiratory syncytial virus (RSV) in a rural and an urban setting, South Africa, 2016-2017	Cheryl	Cohen
P 91	AROVA0029	2	CS	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) neutralizing monoclonal antibody (MK-1654) in Healthy Subjects	Antonios	Aliprantis
P 126	AROVA0030	2	EE	Evolutionary dynamics of respiratory syncytial virus genotype BA attachment (G) glycoprotein in Kilifi, coastal Kenya, 2003-2017	Everlyn	Kamau
P 127	AROVA0031	2	EE	Molecular characterization of respiratory syncytial virus in children with repeated infections with subgroup B in the Philippines	Michiko	Okamoto
P 36	AROVA0032	1	VTT	Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during early stage infection.	Winke	Van der Gucht
P 174	AROVA0034	2	IMM	Evaluation of a polyanhydride-based nanoparticle vaccine utilizing RSV M and/or prefusion F	Laura	Stephens
P 175	AROVA0035	2	IMM	Respiratory syncytial virus strain-dependent inflammasome activation influences pathogenesis	Kody	Waldstein
P 128	AROVA0037	2	EE	Molecular characterization of respiratory syncytial viruses circulating in a pediatric cohort in Amman, Jordan	Nidia Isabel	Sequeira Trovao
P 129	AROVA0038	2	EE	Detection of RS virus and multiple respiratory viruses in inpatients with respiratory tract infection by direct real-time RT-LAMP.	Koichi	Hashimoto
P 130	AROVA0039	2	EE	Mortality Associated with Laboratory Confirmed RSV Infection, Connecticut, 2013-2016	Lindsay	Kim
P 131	AROVA0042	2	EE	Respiratory syncytial virus hospitalization during pregnancy in four high-income countries: Results from the PREVENT Network	Sarah	Buchan
P 37	AROVA0043	1	VTT	mRNA vaccines expressing forms of RSV-F protein are immunogenic and protective in rodent models of Respiratory Syncytial Virus infection	Amy	Espeseth
P 132	AROVA0045	2	EE	Assessment of Respiratory Syncytial Virus Surveillance in the United States	Monica	Schroeder
P 133	AROVA0047	2	EE	Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States	Alexey	Ruzin
P 38	AROVA0049	1	VTT	An mRNA Based Vaccine Expressing RSV F is Immunogenic and Protective in Non-Human Primate Models of Respiratory Syncytial Virus Infection	Andrew	Bett
P 5	AROVA0053	1	VIR	In vitro characterization of subgroup A and B recombinant human respiratory syncytial viruses based on clinical isolates	Laurine	Rijsbergen

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 134	AROVA0054	2	EE	Association of respiratory syncytial virus (RSV) severity with candidate SNP variants using the Illumina Golden Gate genotyping platform	Jacqui	Marzec
P 39	AROVA0055	1	VTT	VRC/NIAID/NIH	Lingshu	Wang
P 6	AROVA0056	1	VIR	In vivo comparison of recombinant human respiratory syncytial virus strains based on clinical isolates in cotton rats	Rik	de Swart
P 34	AROVA0057	1	VTT	Efficacy of a virus-like particle (VLP) Respiratory Syncytial Virus (RSV) vaccine candidates in naive and previously infected cotton rat dams and their offspring	Jorge	Blanco
P 7	AROVA0058	1	VIR	Immunogold electron microscopy reveals that nucleolin (NCL) is recruited to the apical membrane of human airway epithelium by human RSV.	Peter	Mastrangelo
P 40	AROVA0059	1	VTT	Evaluation of antibody response and efficacy in cotton rats inoculated with historical RSV strains and challenged with contemporary strains	Annette	Machado
P 135	AROVA0060	2	EE	Mortality in children in the community associated with acute respiratory infections	Mauricio	Caballero
P 176	AROVA0061	2	IMM	The Human Respiratory Syncytial Virus Triggers p53-Dependent expression of innate immune APOBEC3 genes	Wesley	Gladwell
P 177	AROVA0064	2	IMM	PCA assay multi-laboratory study results show good output agreement for some assay formats and sample types	Nancy	Hosken
P 8	AROVA0066	1	VIR	Interaction of the RSV matrix protein with the viral transcriptase	Sarah	Croft
P 42	AROVA0067	1	VTT	Characterization of Potent RSV Neutralizing mAbs isolated from human memory B cells	Xiao	Xiao
P 136	AROVA0068	2	EE	Respiratory Syncytial Virus Burden of Disease and Lethality: 18 years active surveillance in a Pediatric Hospital	Maria Florencia	Lucion
P 137	AROVA0070	2	EE	Respiratory Syncytial Virus (RSV) in Preterm Infants: Epidemiology, Clinical Pattern and Risk Factors in a Pediatric hospital in Argentina.	Maria del Valle	Juarez
P 138	AROVA0071	2	EE	Prevalence of Human Respiratory Syncytial Virus in the Philippines, 1999-2016	Jonjee	Morin
P 43	AROVA0073	1	VTT	Labyrinthopeptin A1 and A2 efficiently inhibit cell entry of human respiratory syncytial virus in vitro and in vivo	Sibylle	Haid
P 139	AROVA0074	2	EE	Circulating strains of Human respiratory syncytial virus in Belgium during seven consecutive respiratory seasons (2011-2018)	Kaat	Ramaekers
P 9	AROVA0075	1	VIR	Mathematical Modeling Identifies Adaptive Immunity as a Key Controller of Respiratory Syncytial Virus (RSV) Titer in Cotton Rats	Darren	Wethington
P 44	AROVA0076	1	VTT	Murine pneumonia virus (MPV) expressing the respiratory syncytial virus (RSV) fusion F glycoprotein from a supernumerary gene is attenuated and immunogenic in rhesus macaques.	Shirin	Munir
P 45	AROVA0077	1	VTT	Effects of the CX3C motif and secreted form of human respiratory syncytial virus (RSV) G protein on immune responses to a parainfluenza virus vector expressing the RSV G protein	Bo	Liang
P 140	AROVA0078	2	EE	Genetic analysis of human respiratory syncytial virus (RSV) F and G sequences from 2015-2017 in South Africa, implications for mAb/vaccine development	Hui	Liu
P 178	AROVA0079	2	IMM	Memory inflation drives tissue-resident memory CD8 T cell maintenance in the lung after intranasal vaccination with MCMV expressing RSV antigens	Kaitlyn	Morabito
P 46	AROVA0080	1	VTT	Pre-Immunity to RSV in human subjects influences the magnitude and quality of response to RSV vaccination	Darin	Edwards
P 10	AROVA0081	1	VIR	Human metapneumovirus cell-to-cell spread in respiratory cell lines and 3D cultures	Nicolas	Cifuentes
P 11	AROVA0082	1	VIR	Differences in RSV Subtypes: Examination of fusion and effectiveness of fusion protein specific monoclonal antibodies	Chelsea	Barrett
P 47	AROVA0083	1	VTT	Examining the effects of MEDI8897 on RSV infection of human bronchial cells and airway cultures	Jonathan	Kinder
P 12	AROVA0084	1	VIR	ELUCIDATION OF THE ROLES OF IRF9 AND IFI6 IN RESPONSE TO RSV INFECTION	Jonathon	Coe
P 92	AROVA0086	2	CS	The p53 tumor suppressor enhances the innate immune response to RSV via a TLR8 SNP	Daniel	Menendez
P 48	AROVA0087	1	VTT	Development and Validation of a Next Generation Sequencing Assay for Detecting Low Level Variants of Respiratory Syncytial Virus	Fiona	Fernandes
P 93	AROVA0089	2	CS	Respiratory syncytial virus (RSV) and influenza infections in children under 2 years of age in Ulaanbaatar, Mongolia and relation to pneumococcal carriage.	Lien Anh Ha	Do
P 49	AROVA0090	1	VTT	The adenoviral vector Ad26 expressing the RSV prefusion F protein shows high potency in preclinical models including neonatal non-human primates, and no predisposition to ERD in rodents, encouraging further development of this vaccine for young infants	Leslie	Van der Fits
P 179	AROVA0091	2	IMM	Differential expression of proteasome/immunoproteasome catalytic subunits by conventional dendritic cells contribute to the CD8 T cell hierarchy in RSV-infected mice	Anthony	DiPiazza
P 141	AROVA0092	2	EE	A model to estimate the potential impact of immunizations on respiratory syncytial virus (RSV) disease burden	Gayle	Langley

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 94	ARSA0093	2	CS	RSV-specific T Cell Responses in the Phase I Clinical Trial of the Stabilized Prefusion RSV F Subunit Protein DS-Cav1	Tracy	Ruckwardt
P 50	ARSA0094	1	VTT	Standardization and Normalization of RSV Neutralization Data from the VRC317 Clinical Trial Using BEI Panel Sera and International Standard 16/284	Man	Chen
P 51	ARSA0095	1	VTT	Improving ability of RSV microneutralization assay to detect G-specific and cross-reactive neutralizing antibodies through immortalized cell line selection	Marina	Boukhalova
P 52	ARSA0096	1	VTT	RSV sequenced directly from infant respiratory secretions reveals selection of minor F protein sequence variants after minimal cell culture passage	Zhenghui	Li
P 95	ARSA0097	2	CS	Molecular diagnostic and serological investigation of RSV in pediatric long term care facilities	Natalie	Thornburg
P 41	ARSA0098	1	VTT	Transplacental Antibody Transfer of Respiratory Syncytial Virus specific IgG in NHP mother-infant pairs	Michael	Citron
P 96	ARSA0099	2	CS	The Importance of Respiratory Syncytial Virus in the Young Febrile Infant Population	Erin	Nicholson
P 142	ARSA0101	2	EE	Long-Term Assessment of Healthcare Utilization Five Years After Respiratory Syncytial Virus Infection in US Infants	Eric	Simoes
P 13	ARSA0103	1	VIR	Stability and conformational transitions of the RSV nucleocapsid	Damián	Alvarez-Paggi
P 32	ARSA0105	1	VIR	Antibody coated Liposomes for Transmucosal vaccination	Mani	Bhargava
P 143	ARSA0107	2	EE	Respiratory syncytial virus infection and disease in infants and young children (ages up to 10 years) observed in Rawalpindi, Pakistan.	Irum	Perveen
P 190	ARSA0108	2	IMM	Pilot study on pulmonary delivery of Palivizumab for severe respiratory syncytial virus infections	Anushi	Rajapaksa
P 97	ARSA0109	2	CS	Digital biomarkers to detect respiratory sickness by measuring; activity, voice, and audible respiratory symptoms	Paul	Wacnik
P 98	ARSA0110	2	CS	INTERIM SAFETY AND IMMUNOGENICITY RESULTS FROM RSV PREFUSION F (DS-CAV1) SUBUNIT PROTEIN VACCINE PHASE I CLINICAL TRIAL (VRC 317)	Michelle	Crank
P 14	ARSA0112	1	VIR	Role of RSV Polymerase in the Antiviral Effect of Ribavirin	Amy	Fung
P 144	ARSA0113	2	EE	Respiratory syncytial virus A and B serotypes among patients hospitalised with severe respiratory illness, South Africa, 2012-2015	Ziyaad	Valley-Omar
P 145	ARSA0114	2	EE	Variation in Respiratory Syncytial Virus (RSV) gene sequence and its impact on viral clearance	Vasanthi	Avadhanula
P 53	ARSA0115	1	VTT	RSV 5C4 Prefusion-Specific Antibody Gene Transfer as a Method of RSV Prevention	Rebecca	Loomis
P 146	ARSA0116	2	EE	Incidence and risk factors associated with respiratory syncytial virus acute respiratory infections in adults aged 65 years old and above residing in long-term care facilities in the Czech Republic (August 2003-May 2004 and August 2004-May 2005)	Thi Lien-Anh	Nguyen
P 54	ARSA0117	1	VTT	Evidence for multiple protective antigenic sites in Respiratory Syncytial Virus G attachment protein in addition to the central conserved domain	Surender	Khurana
P 99	ARSA0119	2	CS	RESPIRATORY SYNCYTIAL VIRUS INFECTION IN THE HOMELESS POPULATION	Jim	Boonyaratanakornkit
P 15	ARSA0121	1	VIR	Secretome profiling of airway epithelial cultures of paediatric origin infected with human respiratory syncytial virus (hRSV)	Olivier	Touzelet
P 147	ARSA0122	2	EE	Genetic variation of Respiratory Syncytial Virus predicts virulence and efficacy of immunoprophylaxis	Farah	Elawar
P 148	ARSA0125	2	EE	Whole genome analysis of local Kenyan and global sequences unravels the epidemiological and molecular evolutionary dynamics of RSV genotype ON1 strains	James	Otieno
P 55	ARSA0126	1	VTT	Multimeric RSV Pre-F antigens presented on a ferritin nanoparticle elicit strong neutralizing responses in animal and human models	Kurt	Swanson
P 100	ARSA0127	2	CS	Low rate of resistance to the RSV fusion inhibitor RV521 in human infection	John	DeVincenzo
P 101	ARSA0130	2	CS	Maternal antibody titers to respiratory syncytial virus (RSV) pre-fusion F protein and risk of severe RSV bronchiolitis in infants	Octavio	Ramilo
P 102	ARSA0132	2	CS	Preliminary Antibody Repertoire Analysis of Memory B Cells from Stabilized Prefusion RSV F Subunit Protein (DS-Cav1)-Vaccinated Adult Volunteers	Maryam	Mukhamedova
P 149	ARSA0133	2	EE	Respiratory Syncytial Virus-Associated Hospitalizations in Young Children -- United States, 2015-2016	Brian	Rha
P 150	ARSA0134	2	EE	Epidemiology of Respiratory Syncytial Virus among Hospitalized Adults, United States, 2017-2018	Lindsay	Kim
P 118	ARSA0135	2	CS	RESPIRATORY SYNCYTIAL VIRUS: POLICY REVIEW AND NEW PUBLIC HEALTH RISKS	Suzanne	Staebler
P 56	ARSA0136	1	VTT	Clinical development of a pediatric live-attenuated RSV vaccine lacking the G attachment protein	Pauline	Verdijk

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 103	AROVA0137	2	CS	Reduced nasal viral load and IFN responses in infants with severe RSV bronchiolitis	Peter	Openshaw
P 16	AROVA0138	1	VIR	RSV strain-dependent growth kinetics, cytopathogenesis and innate immune responses following WD-PBEC infection.	Lindsay	Broadbent
P 57	AROVA0139	1	VTT	Comparative therapeutic potential of ALX-0171 and palivizumab against RSV Memphis 37 and BT2a clinical strains in a RSV/WD-PBEC model.	Lindsay	Broadbent
P 180	AROVA0140	2	IMM	Control of IFN-I responses by the aminopeptidase IRAP in neonatal alveolar macrophages upon RSV infection	Delphyne	Descamps
P 58	AROVA0141	1	VTT	Exciting therapeutic potential of ALX-0171 demonstrated in RSV-infected well-differentiated primary paediatric bronchial epithelial cell (WD-PBEC) cultures.	Lindsay	Broadbent
P 59	AROVA0142	1	VTT	A Statistical Model of RSV Disease in Neonates and Efficacy Prediction for Maternal Vaccines	Bing	Cai
P 151	AROVA0143	2	EE	The Burden of Respiratory Syncytial Virus (RSV) Febrile Illness and RSV-Associated Pneumonia within a Community-based Prospective Birth Cohort in Nicaragua	John	Kubale
P 17	AROVA0144	1	VIR	RSV attributable mortality in Portugal between 2014 and 2018	RAQUEL	GUIOMAR
P 181	AROVA0146	2	IMM	CD32 expressing CD4-positive T cells during pediatric RSV infection	Inés	Sananez
P 60	AROVA0147	1	VTT	Developing SeVRSV as an RSV vaccine and dissecting influences of nuclear hormones on vaccine success	Julia	Hurwitz
P 152	AROVA0148	2	EE	Phylogenetic analysis of known epitopes in human respiratory syncytial virus F and G proteins	Yihui	Chen
P 61	AROVA0150	1	VTT	Characterization of highly potent human monoclonal antibodies targeting different antigenic sites on the pre-fusion RSV-F protein	Harald	Rouha
P 62	AROVA0151	1	VTT	The isolation and characterization of the Respiratory Syncytial Virus NO-P complex paves the way for the rational design of novel antivirals.	Marie	Galloux
P 153	AROVA0152	2	EE	Clinically significant viral respiratory disease in infancy is associated with early recurrent wheeze and asthma in a rural Ecuadorian birth cohort	Jessica	Atwell
P 18	AROVA0153	1	VIR	Epidemiology of Respiratory Syncytial Virus in Antananarivo, Madagascar, 2011-2017: genetic diversity and mechanism of seasonality.	Noroso	Razanajatovo
P 154	AROVA0154	2	EE	Molecular and clinical characteristic of hospitalised respiratory syncytial virus (RSV) infections in children under 2 years of age in Melbourne.	Lien Anh Ha	Do
P 182	AROVA0155	2	IMM	Respiratory Syncytial Virus Infection Predisposes Mice for Allergy-induced Asthma	Jozef	Balla
P 19	AROVA0157	1	VIR	Molecular Characterization of Circulating Respiratory Syncytial Virus (RSV) Genotypes in a Paediatric Clinic, Accra- Ghana	ANNA. ABA	KAFINTU-KWASHIE
P 63	AROVA0159	1	VTT	Structure of RSV-F antigen with a potent neutralizing antibody	Hua	Su
P 104	AROVA0160	2	CS	EDP-938, a Novel, Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus: Preliminary Results of a Phase 1 Study in Healthy Subjects (HS)	Nathalie	Adda
P 183	AROVA0162	2	IMM	A comparison of RSV F protein antibody repertoires in adenoids and peripheral blood from young children	Peter F.	Wright
P 105	AROVA0163	2	CS	Comparison of Demographic and Clinical Characteristics and Outcome of RSV A vs. B.	Varvara	Probst
P 64	AROVA0164	1	VTT	Pre-clinical evaluation of MV-012-968, a live, attenuated respiratory syncytial virus vaccine candidate	Roderick	Tang
P 155	AROVA0166	2	EE	Burden and risk factors for severe human metapneumovirus disease in children from a developing country setting	Romina	Libster
P 20	AROVA0167	1	VIR	Molecular Characterization of Circulating Respiratory Syncytial Virus (RSV) Genotypes in a Paediatric Clinic, Accra- Ghana	ANNA. ABA	KAFINTU-KWASHIE
P 156	AROVA0169	2	EE	In-host evolution of RSV during experimental infection of adult volunteers	Inne	Nauwelaers
P 65	AROVA0170	1	VTT	Removal of single or double N-glycosylation sequons in p27 of the respiratory syncytial virus fusion protein elicits enhanced antibody responses after DNA immunization	Annelies	Leemans
P 66	AROVA0171	1	VTT	Small molecules targeting HRSV M2-1	Jingjing	CAO
P 157	AROVA0172	2	EE	RSV laboratory surveillance in the UK: building on existing ILI systems	Monica	Galiano
P 67	AROVA0173	1	VTT	Functionality of anti-RSV F protein antibodies induced by immunisation with investigational respiratory syncytial virus (RSV) vaccine based on ChAd155 viral vector expressing RSV viral proteins F, N and M2-1 and impact of baseline anti-vector immunity in healthy adults.	Matthew	Snape
P 106	AROVA0174	2	CS	Immune responses after 12-month booster dose of MVA-BN-RSV	Christopher	Heery
P 107	AROVA0175	2	CS	A mixed methods approach to developing a bronchiolitis core outcome set	Paul	McNamara

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 158	AROVA0178	2	EE	The First Laboratory Report of Respiratory syncytial viruses A/B (RSV A/B) among Acute Respiratory Illness Cases in Ethiopia, 2015-2016.	Adamu Tayachew	Mekonnen
P 184	AROVA0179	2	IMM	Development of Luciferase Immunoprecipitation Systems Assay (LIPS) to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein	Lynne	Crim
P 68	AROVA0181	1	VTT	Development of an ELISA-Based Assay to Evaluate Conformation-Specific Immune Responses to an mRNA-Based Vaccine Against Respiratory Syncytial Virus	Pedro J	Cejas
P 69	AROVA0182	1	VTT	In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine	Ernest	Maynard
P 21	AROVA0184	1	VIR	A Mathematical Model to Predict Respiratory Syncytial Virus Kinetics in Infants	Sydney	Busch
P 70	AROVA0185	1	VTT	Antigenic Characterization Prefusionogenic Nanoparticle Vaccine, Prefusion, and Postfusion F against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats	Nita	Patel
P 159	AROVA0186	2	EE	A cluster of respiratory syncytial virus infections in a neonatal intensive care unit: Using molecular epidemiology to better understand transmission -- Louisiana, December 2017	Erica	Rose
P 71	AROVA0187	1	VTT	Respiratory Syncytial Virus (RSV) Prefusionogenic F Nanoparticle Vaccine Compared to Prefusion and Postfusion RSV F: Physical and Antigenic Structure, Immunogenicity, and Protection	Gale	Smith
P 22	AROVA0188	1	VIR	Differential pathogenesis of human metapneumovirus clinical isolates in mouse models	Yu	Zhang
P 72	AROVA0190	1	VTT	Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine for Maternal Immunization	Yen-Huei	Lin
P 23	AROVA0192	1	VIR	High-Throughput Next-Generation Sequencing of Human Respiratory Syncytial Virus Subgroups A and B	Lijuan	Wang
P 24	AROVA0193	1	VIR	International Network For Optimal Resistance Monitoring of RSV (INFORM RSV): An international study to determine the molecular heterogeneity of RSV in children (a ReSViNET study)	Annefleure	Langedijk
P 160	AROVA0197	2	EE	Evolutionary analysis of four consecutive outbreaks of Respiratory Syncytial Virus using complete genomes from Argentina shows multiple introductions and subtype switch.	Stephanie	Goya
P 161	AROVA0198	2	EE	Epidemiology of respiratory syncytial virus infections reported through ILI and sARI surveillance in border province, Mongolia, 2013-2014.	Taro	Kamigaki
P 25	AROVA0199	1	VIR	The RSV G protein interacts with CX3CR1 in THP-1 monocytes	Tiffany	King
P 108	AROVA0200	2	CS	Does prevention of RSV disease by monoclonal antibody result in rebound RSV disease?	Amanda	Driscoll
P 185	AROVA0202	2	IMM	Host genetic and microbial basis of Respiratory Syncytial Virus (RSV) infection outcomes in cotton rats.	Britton	Strickland
P 73	AROVA0203	1	VTT	Binding Kinetics of RSV Prefusionogenic Vaccine to Palivizumab and Serum Polyclonal Antibody	Hanxin	Lu
P 186	AROVA0205	2	IMM	Neutrophil apoptosis is delayed by RSV but increased following migration through RSV infected airway epithelial cells.	Elisabeth	Robinson
P 187	AROVA0207	2	IMM	A novel method of quantifying phagocytosis in neutrophils from infants with RSV.	Elisabeth	Robinson
P 74	AROVA0208	1	VTT	Respiratory Syncytial Virus (RSV) G Protein Immunogens to Produce a Safe, Robust and Durable Immune Response	Harrison	Bergeron
P 26	AROVA0210	1	VIR	RSV infection of STAT2-/- Golden Syrian Hamsters Reproduces the Pathologic Outcomes of RSV Infection of Human Airways.	Raymond	Pickles
P 188	AROVA0211	2	IMM	The investigation of early life innate immune responses to RSV in cystic fibrosis airway epithelium.	Patricia	Coulter
P 109	AROVA0212	2	CS	Potential role of IL-33 in the severity of Respiratory Syncytial Virus infection	Susan	Bueno
P 162	AROVA0214	2	EE	Molecular characterization of respiratory syncytial virus infections in children and adults in Seattle, WA from 2013 to 2016	Emily	Scott
P 75	AROVA0216	1	VTT	Respiratory Syncytial Virus infection in Infant Baboons Enhances Work of Breathing, Tidal Volume and Minute Ventilation.	Robert	Welliver
P 27	AROVA0217	1	VIR	Molecular Characteristics and Seasonality of Respiratory Viruses Detected from Children with Influenza Like Illness in Nepal	Bishnu Prasad	Upadhyay
P 163	AROVA0218	2	EE	Prevalence and seasonality of common viral respiratory pathogens, including Cytomegalovirus in children, between 0-5 years of age in KwaZulu-Natal, an HIV endemic province in South Africa.	Temitayo	Famoroti
P 189	AROVA0219	2	IMM	Interferon-dependent and -independent control of Respiratory Syncytial Virus infection of respiratory epithelial cells	Philippa	Hillyer
P 76	AROVA0220	1	VTT	Efficacy of ChAd155-RSV in the bovine challenge model when administered in the presence of maternal antibodies	Rineke	De Jong
P 164	AROVA0221	2	EE	Acute respiratory infections among school going children: Preliminary observations from a one-year longitudinal study.	Irene	Adema
P 165	AROVA0222	2	EE	The rate of laboratory confirmed RSV infection over five consecutive seasons in individuals aged 65 years or more	Chisha	Sikazwe

Poster Number	Abstract Reference	Poster Session	Category	Title	Presenting Author	
P 77	AROVA0224	1	VTT	Structure-based design of a fully synthetic RSV vaccine candidate based on conformationally stabilized epitope mimetics and self-assembling lipopeptides	Arin	Ghasparian
P 28	AROVA0225	1	VIR	RSV infection in Normal Human Bronchial Epithelial cells induces filopodia and increases cell migration.	Masfique	Mehedi
P 78	AROVA0226	1	VTT	Using household social contact patterns to estimate transmission of respiratory syncytial virus within and between households of a rural coastal population in Kenya.	Moses	Kiti
P 110	AROVA0227	2	CS	RSV-associated respiratory deaths among Zambian Infants: an interim analysis of the first year of the Zambia Pertussis RSV Infant Mortality Estimation (ZPRIME) Study.	Christopher	Gill
P 112	AROVA0228	2	CS	The RSV Human Viral Challenge Model: Over a decade of experience, what have we learnt?	Rob	Lambkin-Williams
P 111	AROVA0229	2	CS	Development of EIA Assays to Detect and Quantify Antibody Response to Respiratory Syncytial Virus in Humans	Samadhan	Jadhao
P 113	AROVA0230	2	CS	Human viral challenge model, A systematic analysis of placebo population data from six RSV studies	Nicolas	Noulin
P 114	AROVA0231	2	CS	Use of qualitative integrated Cyclor PCR to trigger therapeutic/placebo dosing in human experimental infection: a retrospective analysis	Nicolas	Noulin
P 79	AROVA0233	1	VTT	Generation of RSV M-based virus-like particles	Binh	Ha
P 80	AROVA0234	1	VTT	Structurally Informed Phylogenetic Models for RSV F Gene Providing Insight of Vaccine Design	Justin	Bahl
P 166	AROVA0237	2	EE	An evaluation of existing clinical case definitions for respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI)	Janet	Englund
P 29	AROVA0238	1	VIR	Determinants of survival time among patients who were admitted with respiratory infection and died in a county referral hospital in Kenya, 2016	Lilian	Mayieka
P 81	AROVA0239	1	VTT	The effectiveness of Trino-IB on rat infected with respiratory syncytial virus (RSV).	Elijah Kolawole	OLADIPO
P 82	AROVA0240	1	VTT	Enhancing the immunogenicity and attenuation of respiratory syncytial virus vaccine candidates by altering NS1 function	Michael	Teng
P 30	AROVA0241	1	VIR	Severe RSV infections in children and elderly during 2017/2018 winter season	RAQUEL	GUIOMAR
P 167	AROVA0242	2	EE	Comparative Genomic Analysis of Human Respiratory Syncytial Virus Subgroups A and B from Nigeria	Elijah Kolawole	OLADIPO
P 116	AROVA0243	2	CS	Longitudinal IFN- γ plasma concentrations and persistent wheezing in infants with RSV Bronchiolitis	Rosa	Rodriguez
P 115	AROVA0244	2	CS	The utilisation of enhanced assay strategies for the RSV human challenge model	Andrew	Catchpole
P 31	AROVA0246	1	VIR	RSV binds Streptococcus pneumoniae via PBP1a increasing its virulence and antibiotic sensitivity	Claire	Smith
P 168	AROVA0249	2	EE	National Center for Biotechnology Information (NCBI) human respiratory syncytial virus (HRSV) resources	Eneida	Hatcher
P 83	AROVA0250	1	VTT	Feasibility of evaluating the impact of RSV prevention in infancy on prevalence of asthma and recurrent wheeze among 10-14 year old Native American children	Jessica	Atwell
P 84	AROVA0252	1	VTT	Rational, stable attenuation of human respiratory syncytial virus for live vaccines by deletion and insertion of amino acids in the hinge region between the mRNA capping and methyltransferase domains of the large polymerase protein	Miaoge	Xue
P 169	AROVA0253	2	EE	Molecular epidemiology of Respiratory Syncytial Virus across global and local scales	Justin	Bahl
P 170	AROVA0254	2	EE	A study to evaluate transmissibility among children aged under 5 years in households and its application to a cohort community in the Philippines	Hirono	Otomaru
P 85	AROVA0256	1	VTT	Selecting vaccine antigens against respiratory syncytial virus: glycoprotein modulation of antibody production through Toll-like receptor 4	Juan	Gutman
P 86	AROVA0258	1	VTT	Economic burden of RSV disease and cost-effectiveness of interventions against RSV in 72 Gavi eligible countries	Mark	Jit
P 87	AROVA0259	1	VTT	Selected plant derived compounds with anti RSV activity.	Cynthia	Mathew
P 88	AROVA0260	1	VTT	Characterization of a wild type hRSV human challenge stock (RSV-NICA) in cotton rats	Martin	Schutten
P 89	AROVA0261	1	VTT	An MVA based RSV vaccine protects mice against RSV challenge by inducing antibodies, including mucosal IgA, as well as T cell responses, all of which are required for complete protection	Kathrin	Endt
P 117	AROVA0263	2	CS	RSV DISEASE IN INFANTS AND POLYMORPHISMS IN IFNAR1	Sofia	Laudanno